

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No	Serial No.
				C-3169/1/US	09/451,641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant	
				Gao, D. et al.	
				Filing Date	Group No
				November 30, 1999	1615

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Filing Date if Appropriate
S.T	4,895,726	Jan 23, 1990	Curtet et al.	424	456	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Translation	
						Yes	No
S.T	FP 0 001 247	Apr 4, 1979	Kanebo	A61K	9/18		
	EP 0 256 933	Feb 24, 1988	Ethypharm	A61K	31/235		X
	EP 0 330 532	Aug 30, 1989	Fournier Industrie et Santé	A61K	9/16		X
	WO 96/38131	Dec 5, 1996	Glaxo	A61K	9/14		
S.T	WO 00/15195	Mar 23, 2000	Nycomed	A61K	9/16		

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

S.T	Amidon et al (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of <i>in vitro</i> drug product dissolution and <i>in vivo</i> bioavailability. <i>Pharmaceutical Research</i> 12(3), 413-420.
	Ansel (1985) <i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed. Philadelphia: Lea & Febiger. Page cited: vii (first page of Contents).
	Aulton, ed. (1988) <i>Pharmaceutics: The Science of Dosage Form Design</i> . Edinburgh: Churchill Livingstone. Pages cited: 8, 156, 311, 330.
	Basit et al. (2001) The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly water-soluble drugs. <i>Pharmaceutical Research</i> 18(8), 1146-1150.
	Bauer et al. (1991) <i>Pharmazeutische Technologie</i> , 3rd ed. Stuttgart: Verlag. Pages cited: 104, 203.
	Berry & Nash, ed. (1993) <i>Pharmaceutical Process Validation</i> , 2nd ed. New York: Marcel Dekker. Pages cited: 174-181.
	British Pharmacopoeia 1993. Pages cited: Vol. I, 316; Vol. II, 753.
	Fincher et al. (1965) Effect of particle size on gastrointestinal absorption of sulfisoxazole in dogs. <i>J. Pharm. Sci.</i> 54(5), 704-708.
	Ghosh et al (1998) Product development studies on the tablet formulation of ibuprofen to improve bioavailability. <i>Drug Development & Industrial Pharmacy</i> 24(5), 473-477.
	Gibaldi (1991) <i>Biopharmaceutics and Clinical Pharmacokinetics</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 51, 52, 62.
	Hubbard et al. (1996) SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute non-surgical pain model. <i>J. Invest. Med.</i> 44(3), 293A.
S.T	Hubbard et al. (1996) SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. <i>Arthritis & Rheumatism</i> 39 (Suppl. 9), S226, abstract 1188.

Examiner	Date Considered
S.T	11/12/99

*Examiner Initial if citation considered whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.	Serial No.
			C-3169/1/US	09/451,641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant		
		Gao, D. et al.		
		Filing Date	Group No	
		November 30, 1999	1615	
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)				
S.T.	Hubbard et al. (1997) Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. <i>Arthritis & Rheumatism</i> 40, S51, abstract 125.			
	Kanenawa et al. (1973) Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior. <i>Chem. Pharm. Bull.</i> 22(8), 1699-1705.			
	Kanenawa et al. (1978) Dissolution of slightly soluble drugs. IV. Effect of particle size of sulfonamides on <i>in vitro</i> absorption rate, and their relation to solubility. <i>Chem. Pharm. Bull.</i> 26(3), 813-826.			
	Lachman et al., ed. (1986) <i>The Theory and Practice of Industrial Pharmacy</i> , 3rd ed. Philadelphia: Lea & Febiger. Pages cited: 21-45, 321-328.			
	Levy (1963). Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. <i>Amer. J. Pharm.</i> , March 1963, 78-92.			
	List (1985) <i>Arzneiformenlehre</i> , 4th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft. Pages cited: 210, 523.			
	Martin (1993) <i>Physical Pharmacy</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 331, 423-436.			
	Ridolfo et al. (1979) Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. <i>J. Pharm. Sci.</i> 68(7), 850-852.			
	Sprowls (1963) <i>Prescription Pharmacy</i> . Philadelphia: Lippincott. Page cited: 56.			
	Voigt (1984) <i>Lehrbuch der Pharmazeutischer Technologie</i> , 5th ed. Basel: Verlag. Pages cited: 471, 472, 637.			
	Wade & Weller (1994) <i>Handbook of Pharmaceutical Excipients</i> , 2nd ed. Washington: American Pharmaceutical Association. Pages cited: v, vi (Contents pages), 141, 163, 252, 280, 433, 448.			
	Wadke et al. (1989) Preformulation testing. In Lieberman et al., ed.: <i>Pharmaceutical Dosage Forms: Tablets</i> , Vol. 1. New York: Marcel Dekker. Pages cited: 5, 6.			
S.T.	Zhao et al. (1997) Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. <i>Arthritis & Rheumatism</i> 40 (Suppl. 9), S88, abstract 348.			
Examiner	Date Considered	S.T. 11/12/02		
*Examiner	Initial if citation considered; whether or not citation is in conformance with MPEP §609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			